semglee vs semaglutide Vs. Zepbound: Weight Loss Differences, Side Effects & Dosage Semaglutide vs. Tirzepatide for weight

03/07/24 Opdivo (nivolumab) New indication March 7, 2024 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC)

We recommend at least two or three baseline measurements over a couple of weeks to account for natural diurnal and day-to-day fluctuations

Baseline Measurements: Includes body weight, waist circumference, blood pressure, and fasting blood tests

By week 12, most patients report 8-15 pounds lost, though individual results vary based on starting weight, diet quality, and activity level

Gluten-free for diabetes: Metabolic miracle or myth